TREATMENT OF THE CHRONIC FATIGUE SYNDROME - A REVIEW AND PRACTICAL GUIDE

被引:19
作者
BLONDELHILL, E [1 ]
SHAFRAN, SD [1 ]
机构
[1] UNIV ALBERTA HOSP,WALTER MACKENZIE HLTH SCI CTR,DEPT MED,DIV INFECT DIS,8440-112 ST,EDMONTON T6G 2B7,ALBERTA,CANADA
关键词
D O I
10.2165/00003495-199346040-00005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The chronic fatigue syndrome (CFS) was formally defined in 1988 to describe a syndrome of severe and disabling fatigue of uncertain aetiology associated with a variable number of somatic and/or psychological symptoms. CFS has been reported in most industrialised countries and is most prevalent in women aged between 20 and 50 years. Despite occasional claims to the contrary, the aetiology of CFS remains elusive. Although abnormalities in tests of immune function and cerebral imaging have been described in variable numbers of CFS patients, such findings have been inconsistent and cannot be relied upon, either to establish or exclude the diagnosis. Thus, diagnosis rests on fulfilment of the Centers for Disease Control case definition which was revised in 1992. This case definition remains somewhat controversial, largely due to its subjectiveness. The mainstay of treatment is establishing the diagnosis and educating the patient about the illness. An empathetic clinician can stop further consultations elsewhere ('doctor shopping') and subsequent excessive investigations, which frequently occur in such patients. Most patients should undertake a trial of antidepressant therapy, even if major depression is not present. The choice of antidepressant drug should tailor the tolerability profile to relief of particular CFS symptoms, such as insomnia or hypersomnia. Failure to improve within 12 weeks warrants an alternative antidepressant agent of another class. Many other drugs have been reported anecdotally to be beneficial, but no therapy has been demonstrated to be reproducibly useful in double-blind, placebo-controlled clinical trials with an adequate duration of follow-up.
引用
收藏
页码:639 / 651
页数:13
相关论文
共 102 条
[1]  
ADOLPHE AB, 1988, AM J MED, V85, P892
[2]  
Anderson J.A., 1986, J ALLERGY CLIN IMMUN, V78, P271, DOI DOI 10.1016/S0091-6749(86)80073-2
[3]   POSTVIRAL FATIGUE SYNDROME - PERSISTENCE OF ENTEROVIRUS RNA IN MUSCLE AND ELEVATED CREATINE-KINASE [J].
ARCHARD, LC ;
BOWLES, NE ;
BEHAN, PO ;
BELL, EJ ;
DOYLE, D .
JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 1988, 81 (06) :326-329
[4]  
ARNOLD DL, 1984, LANCET, V1, P1367
[5]   THE POSTVIRAL FATIGUE SYNDROME - AN ANALYSIS OF THE FINDINGS IN 50 CASES [J].
BEHAN, PO ;
BEHAN, WMH ;
BELL, EJ .
JOURNAL OF INFECTION, 1985, 10 (03) :211-222
[6]   EFFECT OF HIGH-DOSES OF ESSENTIAL FATTY-ACIDS ON THE POSTVIRAL FATIGUE SYNDROME [J].
BEHAN, PO ;
BEHAN, WMH ;
HORROBIN, D .
ACTA NEUROLOGICA SCANDINAVICA, 1990, 82 (03) :209-216
[7]  
BEHAN PO, 1988, CRIT REV NEUROBIOL, V4, P157
[8]   COXSACKIE-B VIRUSES AND MYALGIC ENCEPHALOMYELITIS [J].
BELL, EJ ;
MCCARTNEY, RA ;
RIDING, MH .
JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 1988, 81 (06) :329-331
[9]  
BOULWARE DW, 1990, POSTGRAD MED, V87, P211
[10]   FREQUENCY OF CHRONIC ACTIVE EPSTEIN-BARR VIRUS-INFECTION IN A GENERAL MEDICAL-PRACTICE [J].
BUCHWALD, D ;
SULLIVAN, JL ;
KOMAROFF, AL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1987, 257 (17) :2303-2307